$SYRA
Syra Health Corp Stock $syra

$syra Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011121 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.752M	$1.766M	$5.515M
YoY Change	47.26%	-68.56%	-1.87%
Cost Of Revenue	$1.573M	$1.184M	$4.103M
YoY Change	51.26%	-74.01%	-10.02%
Gross Profit	$179.3K	$582.0K	$1.412M
YoY Change	19.52%	-45.18%	33.2%
Gross Profit Margin	10.23%	32.95%	25.6%
Selling, General & Admin	$402.3K	$1.316M	$4.011M
YoY Change	-55.8%	-58.05%	27.73%
% of Gross Profit	224.37%	226.07%	284.06%
Research & Development	$277.5K	$240.1K	$240.1K
YoY Change
% of Gross Profit	154.81%	41.24%	17.0%
Depreciation & Amortization	$12.55K	$12.36K	$48.77K
YoY Change	25.45%	23.6%	228.42%
% of Gross Profit	7.0%	2.12%	3.45%
Operating Expenses	$1.623M	$1.568M	$4.299M
YoY Change	76.44%	-50.24%	36.49%
Operating Profit	-$1.444M	-$986.2K	-$2.888M
YoY Change	87.53%	-52.81%	38.16%
Interest Expense	$4.077K	-$9.120K	-$50.75K
YoY Change	-140.77%	-67.97%	69.17%
% of Operating Profit
Other Income/Expense, Net	-$3.096K		-$50.74K
YoY Change	-72.88%		78.24%
Pretax Income	-$1.447M	-$995.3K	-$2.938M
YoY Change	83.17%	-53.01%	38.6%
Income Tax
% Of Pretax Income
Net Earnings	-$1.447M	-$995.3K	-$2.938M
YoY Change	83.17%	-53.01%	38.6%
Net Earnings / Revenue	-82.58%	-56.35%	-53.28%
Basic Earnings Per Share	-$0.22		-$0.60
Diluted Earnings Per Share	-$0.22	-$0.16	-$0.60
COMMON SHARES
Basic Shares Outstanding	5.732M shares	13.92M shares	4.878M shares
Diluted Shares Outstanding	6.495M shares		4.878M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.238M	$3.280M	$3.280M
YoY Change	439.66%
Cash & Equivalents	$3.238M	$3.280M
Short-Term Investments
Other Short-Term Assets	$381.9K	$389.8K
YoY Change		75.34%
Inventory
Prepaid Expenses	$233.5K	$316.7K
Receivables	$827.8K	$1.111M	$1.111M
Other Receivables	$381.9K	$389.8K	$389.8K
Total Short-Term Assets	$4.448M	$4.781M	$4.781M
YoY Change	244.78%	235.11%	234.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$72.05K	$142.2K	$142.2K
YoY Change	-73.32%	26.38%	-52.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$103.9K	$142.2K	$142.2K
YoY Change	-89.72%	-84.08%	-84.03%
TOTAL ASSETS
Total Short-Term Assets	$4.448M	$4.781M	$4.781M
Total Long-Term Assets	$103.9K	$142.2K	$142.2K
Total Assets	$4.552M	$4.923M	$4.923M
YoY Change	97.89%	112.24%	112.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$645.6K	$463.0K	$463.0K
YoY Change	37.35%		5.23%
Accrued Expenses	$319.7K	$262.2K	$262.2K
YoY Change	-3.12%	9.65%	-27.17%
Deferred Revenue
YoY Change
Short-Term Debt	$99.02K	$184.9K	$184.9K
YoY Change	-66.99%		-75.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.102M	$910.1K	$910.1K
YoY Change	1.12%	-41.15%	-41.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.102M	$910.1K	$910.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.102M	$910.1K	$910.1K
YoY Change	-53.69%	-43.46%	-43.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.512M	-$5.065M
YoY Change		138.17%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.449M	$4.013M	$4.013M
YoY Change
Total Liabilities & Shareholders Equity	$4.552M	$4.923M	$4.923M
YoY Change	97.89%	112.24%	112.21%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.447M	-$995.3K	-$2.938M
YoY Change	83.17%	-53.01%	38.6%
Depreciation, Depletion And Amortization	$12.55K	$12.36K	$48.77K
YoY Change	25.45%	23.6%	228.42%
Cash From Operating Activities	-$800.7K	-$1.757M	-$2.759M
YoY Change	1501.49%	9.13%	22.95%
INVESTING ACTIVITIES
Capital Expenditures	$5.619K	$0.00	$15.25K
YoY Change	-43.81%	-100.0%	-87.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$5.619K	$0.00	-$15.25K
YoY Change	-43.81%	-100.0%	-87.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.332M
YoY Change			129.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$764.2K	5.019M	6.051M
YoY Change	17.58%	606.92%	166.72%
NET CHANGE
Cash From Operating Activities	-$800.7K	-1.757M	-2.759M
Cash From Investing Activities	-$5.619K	0.000	-15.25K
Cash From Financing Activities	$764.2K	5.019M	6.051M
Net Change In Cash	-$42.12K	3.262M	3.277M
YoY Change	-107.14%	-422.98%	-3489.6%
FREE CASH FLOW
Cash From Operating Activities	-$800.7K	-$1.757M	-$2.759M
Capital Expenditures	$5.619K	$0.00	$15.25K
Free Cash Flow	-$806.4K	-$1.757M	-$2.774M
YoY Change	1243.94%	2.15%	17.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001922335
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties		usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet		usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	SYRA	Initial Recognition Of Rightofuse Asset And Lease Liability InitialRecognitionOfRightofuseAssetAndLeaseLiability		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	SYRA	Cancellation Of Common Stock CancellationOfCommonStock		usd
CY2022	us-gaap	Loans Assumed1 LoansAssumed1		usd
CY2022	us-gaap	Notes Issued1 NotesIssued1		usd
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2023Q4	SYRA	Employee Retention Tax Credit Receivables EmployeeRetentionTaxCreditReceivables		usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent		usd
CY2023Q4	SYRA	Prepaid Licensing And Office Fees PrepaidLicensingAndOfficeFees		usd
CY2023Q4	SYRA	Retainers Paid On Professional Services RetainersPaidOnProfessionalServices		usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent		usd
CY2023Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent		usd
CY2022	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest		usd
CY2023	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021Q4	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeitures Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2022Q4	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023Q4	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber		shares
CY2023Q4	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41822
CY2023	dei	Entity Registrant Name EntityRegistrantName	SYRA HEALTH CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-4027995
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1119 Keystone Way N. #201
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
CY2023	dei	City Area Code CityAreaCode	(463)
CY2023	dei	Local Phone Number LocalPhoneNumber	345-8950
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	SYRA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5731587	shares
CY2023	dei	Auditor Firm AuditorFirmId	2738
CY2023	dei	Auditor Name AuditorName	M&K CPAS, PLLC
CY2023	dei	Auditor Location AuditorLocation	Houston, TX
CY2023Q4	us-gaap	Cash Cash	3280075	usd
CY2022Q4	us-gaap	Cash Cash	3344	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	389787	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	222302	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4781110	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1426743	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	596118	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78974	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112493	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63199	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	184288	usd
CY2023Q4	us-gaap	Assets Assets	4923283	usd
CY2022Q4	us-gaap	Assets Assets	2319642	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198978	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	239117	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63199	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121089	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	184904	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	750551	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	910072	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1546345	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63199	usd
CY2023Q4	us-gaap	Liabilities Liabilities	910072	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1609544	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	SYRA	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2022Q4	SYRA	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9071745	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2832308	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5064955	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2126612	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4013211	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	710098	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4923283	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2319642	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5515144	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5617706	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4103244	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4555924	usd
CY2023	us-gaap	Gross Profit GrossProfit	1411900	usd
CY2022	us-gaap	Gross Profit GrossProfit	1061782	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	2292295	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	1524971	usd
CY2023	us-gaap	Depreciation Depreciation	48771	usd
CY2022	us-gaap	Depreciation Depreciation	14849	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4299499	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3151477	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4877861	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3041085	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3041085	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2887599	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2089695	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2942	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	63	usd
CY2023	us-gaap	Interest Expense InterestExpense	53686	usd
CY2022	us-gaap	Interest Expense InterestExpense	28533	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50744	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28470	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2938343	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2118165	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4877861	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7147	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2322500	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	510000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2910	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2118165	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	710098	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	710098	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1472460	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32831	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4736165	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4013211	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4013211	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2938343	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2118165	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	95563	usd
CY2023	us-gaap	Depreciation Depreciation	48771	usd
CY2022	us-gaap	Depreciation Depreciation	14849	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	14076	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	510000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	32831	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2910	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59547	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	940470	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	50614	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-203110	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	200798	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-121089	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	30603	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	392276	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-3200	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-82418	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-22679	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	163675	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-121089	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-95563	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2759068	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2244065	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15251	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121260	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15251	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121260	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	596118	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	185692	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5332283	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2322500	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	300000	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	2819275	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1050551	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2082800	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1295010	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	94000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2268657	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3276731	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-96668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1095000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	288200	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1455000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6051050	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100012	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3280075	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	36226	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	11651	usd
CY2022	SYRA	Initial Recognition Of Rightofuse Asset And Lease Liability InitialRecognitionOfRightofuseAssetAndLeaseLiability	131187	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1472460	usd
CY2023	SYRA	Cancellation Of Common Stock CancellationOfCommonStock	42	usd
CY2023	us-gaap	Loans Assumed1 LoansAssumed1	200010	usd
CY2023	us-gaap	Notes Issued1 NotesIssued1	370596	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zpUjEc683eah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zqTFOA8CF9g9">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zNlus4SSpQgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z0RBozeos0vh">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zEXxrBt7ALL7" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5520	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	4533	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	596118	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1928133	usd
CY2022Q4	SYRA	Employee Retention Tax Credit Receivables EmployeeRetentionTaxCreditReceivables	116361	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39000	shares
CY2023	us-gaap	Revenues Revenues	5515144	usd
CY2022	us-gaap	Revenues Revenues	5617706	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3280075	usd
CY2023Q4	SYRA	Working Capital WorkingCapital	3871038	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5064955	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1455000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5332283	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	94000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	288200	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1901100	shares
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	73069	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	28734	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	316718	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	20040	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	10711	usd
CY2022Q4	SYRA	Prepaid Licensing And Office Fees PrepaidLicensingAndOfficeFees	16456	usd
CY2022Q4	SYRA	Retainers Paid On Professional Services RetainersPaidOnProfessionalServices	30000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	389787	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	222302	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63827	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15056	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78974	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112493	usd
CY2023	us-gaap	Depreciation Depreciation	48771	usd
CY2022	us-gaap	Depreciation Depreciation	14849	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	148924	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	212660	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50054	usd
CY2022Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	4874	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	18777	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2806	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198978	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	239117	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04	pure
CY2023	SYRA	Investment Retirement Account Contribution Expenses InvestmentRetirementAccountContributionExpenses	88327	usd
CY2023Q4	SYRA	Accrued Retirement Contributions AccruedRetirementContributions	8778	usd
CY2022	SYRA	Investment Retirement Account Contribution Expenses InvestmentRetirementAccountContributionExpenses	28534	usd
CY2022Q4	SYRA	Accrued Retirement Contributions AccruedRetirementContributions	4874	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	184288	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	750551	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	750551	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1472460	usd
CY2023	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	27054	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	14397	usd
CY2023	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	17460	usd
CY2023	us-gaap	Interest Expense Medium Term Notes InterestExpenseMediumTermNotes	8966	usd
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	14076	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	206	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	60	usd
CY2023	us-gaap	Interest Expense InterestExpense	53686	usd
CY2022	us-gaap	Interest Expense InterestExpense	28533	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	185692	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	184904	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	121089	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	184288	usd
CY2023	SYRA	Operating Lease Interest Expense OperatingLeaseInterestExpense	7438	usd
CY2022	SYRA	Operating Lease Interest Expense OperatingLeaseInterestExpense	8733	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	128527	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	175555	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63199	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63199	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121089	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63199	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63199	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	184288	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575	pure
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	121089	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	107013	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	131187	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64263	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63199	usd
CY2022Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	28000	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2002850	shares
CY2023	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice	6.40
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	242500	shares
CY2023	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeitures Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice	-6.50
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1760350	shares
CY2023Q4	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	6.39
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y9M
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	198383	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0445	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0471	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.12	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.15	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21041	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current And Noncurrent DeferredCompensationLiabilityCurrentAndNoncurrent	196955	usd
CY2022Q3	SYRA	Number Of Options Vested NumberOfOptionsVested	0.25	pure
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.93	pure
CY2022Q3	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.0303	pure
CY2022Q3	SYRA	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice	0.9328
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	30317	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2910	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	39000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	39000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	112750	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	140750	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y6M29D
	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4637000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1731000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.24	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.24	pure
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1029723	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	332400	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1029723	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	332400	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-011121-index-headers.html	Edgar Link	pending
0001493152-24-011121-index.html	Edgar Link	pending
0001493152-24-011121.txt	Edgar Link	pending
0001493152-24-011121-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syra-20231231.xsd	Edgar Link	pending
syra-20231231_def.xml	Edgar Link	unprocessable
syra-20231231_lab.xml	Edgar Link	unprocessable
syra-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
syra-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SYRA
Syra Health Corp Stock $syra

2024 Q1 Form 10-K Financial Statement

#000149315224011121 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SYRA Syra Health Corp Stock $syra

2024 Q1 Form 10-K Financial Statement

#000149315224011121 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SYRA
Syra Health Corp Stock $syra